Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

30, missing market expectations of 238 million pounds, while sales of shingles vaccine, Shingrix, fell 7% to 739 million pounds, also below estimates in a company compiled consensus. Walmsley told ...

“These data support our efforts to bring a new shingles vaccine to global markets,” stated George Simeon, Curevo’s Chief Executive Officer. “Though somewhat unsurprising, given amezosvatein also ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older receive two doses of Shingrix, the shingles vaccine, two to six months ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At the end of the company's ...

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.